Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.61 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.56 |
| ▸ | GHSR | Q92847 | 2/20 | 0.52 |
| ▸ | LIPE | Q05469 | 1/20 | 0.49 |
| ▸ | ABHD6 | Q9BV23 | 3/20 | 0.47 |
| ▸ | ESR1 | P03372 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | JAK2 | O60674 | 2/20 | 0.43 |
| ▸ | JAK3 | P52333 | 2/20 | 0.43 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.41 |
| ▸ | STS | P08842 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25430802 | 1.00 | NR1H2 (0.61) | NR1H2ESR2GHSRLIPEABHD6 | |
| SCHEMBL31566067 | 0.89 | ABHD6 (0.52) | NR1H2ESR2GHSRLIPEABHD6 | |
| SCHEMBL29097988 | 0.86 | NR1H2 (0.55) | NR1H2ESR2GHSRLIPEABHD6 | |
| SCHEMBL30199290 | 0.86 | NR1H2 (0.55) | NR1H2ESR2GHSRLIPEABHD6 | |
| SCHEMBL30199596 | 0.86 | NR1H2 (0.63) | NR1H2ESR2GHSRABHD6ESR1 | |
| SCHEMBL30199574 | 0.86 | NR1H2 (0.63) | NR1H2ESR2GHSRABHD6ESR1 | |
| SCHEMBL13718183 | 0.86 | NR1H2 (0.63) | NR1H2ESR2ABHD6ESR1MAPT | |
| SCHEMBL31021995 | 0.86 | NR1H2 (0.63) | NR1H2ESR2ABHD6ESR1MAPT | |
| SCHEMBL31565846 | 0.86 | HRH3 (0.52) | ESR2GHSRLIPEABHD6ESR1 | |
| SCHEMBL30970511 | 0.86 | NR1H2 (0.57) | NR1H2ESR2GHSRLIPEABHD6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250382293-A1 | COMPOUNDS AND METHODS FOR YAP/TEAD MODULATION AND INDICATIONS THEREFOR | Opna Bio SA (CH) | 2025-12-18 | — | — | US | disclosed |
| EP-4654971-A1 | COMPOUNDS AND METHODS FOR YAP/TEAD MODULATION AND INDICATIONS THEREFOR | Opna Bio SA (CH) | 2025-12-03 | — | — | EP | disclosed |
| US-20250129028-A1 | COMPOUNDS AND METHODS FOR YAP/TEAD MODULATION AND INDICATIONS THEREFOR | Opna Bio SA (CH) | 2025-04-24 | — | — | US | disclosed |
| EP-4469036-A2 | COMPOUNDS AND METHODS FOR YAP/TEAD MODULATION AND INDICATIONS THEREFOR | Opna Bio SA (CH) | 2024-12-04 | — | — | EP | disclosed |
| WO-2024159081-A1 | COMPOUNDS AND METHODS FOR YAP/TEAD MODULATION AND INDICATIONS THEREFOR | Opna Bio SA (CH) | 2024-08-02 | — | — | WO | disclosed |
| CN-117956996-A | Compounds and methods for YAP/TEAD modulation and indications therefor | OPNA 生物公司 | 2024-04-30 | — | — | CN | disclosed |
| WO-2023147063-A2 | COMPOUNDS AND METHODS FOR YAP/TEAD MODULATION AND INDICATIONS THEREFOR | Opna Bio SA (CH) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129028-A1 | COMPOUNDS AND METHODS FOR YAP/TEAD MODULATION AND INDICATIONS THEREFOR | YAP1, YES1, LATS1 | NR1H2 174/4885ESR2 797/4885GHSR 223/4885 |
| US-20250382293-A1 | COMPOUNDS AND METHODS FOR YAP/TEAD MODULATION AND INDICATIONS THEREFOR | YAP1, YES1, TEAD2 | NR1H2 200/4885ESR2 1051/4885GHSR 308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.